Drug Trial Radar · NCT02327169
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Feb 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Jan 14, 2015
Primary completion
Jul 2, 2018
Study completion Jul 2, 2018
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
Conditions
- Advanced Nonhematologic Malignancies
Interventions
MLN2480Drug
MLN2480 tablets.
MLN0128Drug
MLN0128 capsules.
AlisertibDrug
Alisertib tablets.
PaclitaxelDrug
Paclitaxel IV infusion.
CetuximabDrug
Cetuximab IV infusion.
IrinotecanDrug
Irinotecan IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)
- Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Day 1, Cycle 1 through 30 days after the last dose in Cycle 1 (up to 8 weeks)
- Maximum Tolerated Dose (MTD) for MLN2480Time frame: Day 1, Cycle 1 up to 28 days
- Recommended Phase 2 Dose (RP2D) of MLN2480Time frame: Day 1, Cycle 1 up to 28 days
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Fox Chase Cancer Center
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Institut Bergonie
Bordeaux, Gironde, France
Institut Claudius Regaud-Oncopole
Toulouse, Haute Garonne, France
Institut Gustave Roussy
Villejuif, Val De Marne, France
Hospital Universitari Vall d'Hebron
Barcelona, Spain
START Madrid. Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria
Málaga, Spain
Sarah Cannon Research Institure UK
London, Greater London, United Kingdom
The Chrisie
Manchester, Greater Manchester, United Kingdom
Churchill Hospital
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.